; (6) review the impact or potential impact of fentanyl-related controls by class on scientific and biomedical research; and (7) evaluate the processes used to obtain or modify Federal authorization to conduct research with fentanyl-related substances, including by— (A) identifying opportunities to reduce unnecessary burdens on persons seeking to research fentanyl-related substances; (B) identifying opportunities to reduce any redundancies in the responsibilities of Federal agencies; (C) identifying opportunities to reduce any inefficiencies related to the processes used to obtain or modify Federal authorization to conduct research with fentanyl-related substances; (D) identifying opportunities to improve the protocol review and approval process conducted by Federal agencies